search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

The FDA approved approved letermovir (Prevymis) to help prevent cytomegalovirus (CMV) infections and disease in adults previously exposed to the common virus who have received an allogeneic hematopoietic stem cell transplant (HSCT), otherwise known as a bone marrow transplant.

You can find more information here.

Additional Information

For additional drug information, please visit the FDA Web page. For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site